Trending Now
Mustang Bio Inc (NASDAQ: MBIO) Receives Orphan Drug Designation From US...
Mustang Bio Inc (NASDAQ: MBIO) has received an Orphan Drug Designation from the US FDA for its CD20-targeted, autologous CAR T cell therapy, MB-106,...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Reason why ReShape Lifesciences Stock (RSLS) is surging
ReShape Lifesciences Stock More than doubled and last traded at $17.04+10.74 (+170.48%). However, the stock lost quite a bit of steam after...
MAKE IT MODERN
LATEST REVIEWS
BioMarin Pharmaceuticals Inc. (NASDAQ: BMRN) Announce Publication of Valoctocogene Roxaparvovec Study...
BioMarin Pharmaceuticals Inc. (NASDAQ: BMRN) has announced the publication of Phase 3 GENEr8-1 study results of valoctocogene roxaparvovec in the New England Journal of...
MAKE IT MODERN
PERFORMANCE TRAINING
Brickell Biotech Inc. (NASDAQ:BBI) Announce dosing of First Patent In Cardigan II Study Of...
Brickell Biotech Inc. (NASDAQ:BBI) has dosed the first patient in the second US vital Phase 3 clinical trials ("Cardigan II study"). The...
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Focuses On Developing SNS-510, The PDK-1 Inhibitor: Raises $12.1 Million
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) will use all of its resources to develop SNS-510, the first in class PI (PDK-1 inhibitor). According to the data...
Nabriva Therapeutics PLC – ADR (NASDAQ:NBRV) Receive The FDA’s Response After Its NDA Submission...
Nabriva Therapeutics PLC – ADR (NASDAQ:NBRV) recently announced that it received the Food and Drug Administration’s (FDA) complete response letter regarding its New Drug...
Cerecor Inc. (NASDAQ:CERC) Receives IND Approval From The FDA For CERC-002 In Treatment of...
Cerecor Inc. (NASDAQ:CERC) has announced that the FDA has given it a clearance to go on with its proof-of-concept clinical study of the Anti-LIGHT...
CTAD 2020 Picks Cassava Sciences Inc.’s (NASDAQ:SAVA) Phase 2b Sumifilam Study Results For Late...
Cassava Sciences Inc. (NASDAQ:SAVA) has announced that its phase 2b clinical study results for sumifilam have been picked for late-breaking oral presentation by the...
MAKE IT MODERN
